Featured Research

from universities, journals, and other organizations

Vaccine With Promising Cancer-Fighting Abilities Developed

Date:
January 21, 1999
Source:
University Of Michigan
Summary:
Researchers at the University of Michigan Comprehensive Cancer Center have created a vaccine that protects mice against a virus which has recently been associated with certain types of cancer in humans. The virus, called simian virus 40 (SV40), has also been shown to cause cancer in rodents.

Ann Arbor MI---Researchers at the University of Michigan Comprehensive Cancer Center have created a vaccine that protects mice against a virus which has recently been associated with certain types of cancer in humans. The virus, called simian virus 40 (SV40), has also been shown to cause cancer in rodents.

Related Articles


The results are published in the Jan. 20 issue of the Journal of the National Cancer Institute.

The team, led by Martin Sanda, M.D., assistant professor of urology surgery in the U-M Health System, constructed a genetically engineered vaccine containing a gene that elicited an immune response against a tumor challenge.

Mice given the vaccine, called vac-mTag, were found to have potent protection against a lethal mouse cancer caused by SV40.

Simian virus 40 became well-known in the late 1950's and early 1960's when it was discovered that polio vaccines given to nearly 100 million Americans were contaminated with SV40. To date, no study has found any direct evidence that SV40 causes cancer in humans.

SV40 produces T-antigen which was one of the first so-called oncogenes discovered. T-antigen is a large protein that causes tumors, and scientists first used it as a laboratory tool to alter normal cells, causing them to produce tumors. However, recent studies have found T-antigen in three rare, but extremely lethal human cancer types---mesothelioma (lung), osteosarcoma (bone) and ependymoma (brain). Researchers continue to study what role T-antigen actually plays in human tumor biology.

Sanda and his team constructed the vaccine by genetically removing the tumor-causing features from T-antigen, resulting in a protein that carries most of the parts that are recognized by the immune system.

"We made a vaccinia for the purpose of immunization that would cause the production of large amounts of T-antigen, lacking the parts that cause tumors while keeping the immune-activating portions intact," Sanda says. "Basically, we created a safety-modified T-antigen that could potentially be safe to use against the more dangerous full-length T-antigen in humans."

In the study, two groups of mice were vaccinated, one group with vac-mTag and the other with a control vector. Three weeks later, both groups were injected with tumor-causing cells. The group that received the vac-mTag showed a significantly potent immune response to the tumor challenge in both survival and tumor-free survival rates.

"The most significant aspect of our findings is that, using this new vaccinia construct, we can protect animals against T-antigen expressing tumors," Sanda says. Sanda says the next step is to prepare the vaccine for clinical applications. This entails

producing clinical-grade vac-mTag and performing FDA-mandated safety tests before launching a clinical trial for human patients. Sanda says he hopes to set up human trials on the vaccine in collaboration with investigators at Wayne State University in the next year or two.

Sanda says this study contributes to a larger effort. "Using a genetically engineered virus to stimulate the immune system against genetic abnormalities in tumors represents a paradigm with great future potential---that of applying information from cancer gene analysis to craft novel vaccines for cancer prevention.

"The usefulness of this particular vac-mTag vaccine may be greatest in the near future because development of human vaccines is now rigorously supervised to the point that it is unlikely humans will be exposed to SV40 in the future."

The study was performed in collaboration with the laboratory of Nicholas Restifo MD., at the National Cancer Institute and was funded by the National Institute of Health and the American Cancer Society.


Story Source:

The above story is based on materials provided by University Of Michigan. Note: Materials may be edited for content and length.


Cite This Page:

University Of Michigan. "Vaccine With Promising Cancer-Fighting Abilities Developed." ScienceDaily. ScienceDaily, 21 January 1999. <www.sciencedaily.com/releases/1999/01/990121073830.htm>.
University Of Michigan. (1999, January 21). Vaccine With Promising Cancer-Fighting Abilities Developed. ScienceDaily. Retrieved March 5, 2015 from www.sciencedaily.com/releases/1999/01/990121073830.htm
University Of Michigan. "Vaccine With Promising Cancer-Fighting Abilities Developed." ScienceDaily. www.sciencedaily.com/releases/1999/01/990121073830.htm (accessed March 5, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, March 5, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) — Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) — Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) — AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Adults Only Get The Flu Twice A Decade, Researchers Say

Adults Only Get The Flu Twice A Decade, Researchers Say

Newsy (Mar. 4, 2015) — Researchers found adults only get the flu about once every five years. Scientists analyzed how a person&apos;s immunity builds up over time as well. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins